Class / Patent application number | Description | Number of patent applications / Date published |
514680000 | Polycyclo ring system | 54 |
20080306164 | NEW 2-SUBSTITUTED D-HOMO-ESTRA-1,3,5(10)-TRIENES AS INHIBITORS OF 17BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 - The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I | 12-11-2008 |
20090082470 | STAT3 INHIBITING COMPOSITIONS AND METHODS | 03-26-2009 |
20090137687 | Compositions and Methods With Enhanced Therapeutic Activity - This invention relates to novel tricyclic quinone and catechol compositions, compositions containing prodrugs of tricyclic quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g., by oxidative stress) in order to achieve an enhanced anti-tumor response in a patient. | 05-28-2009 |
20090149551 | OXIDIZED cis-TERPENONE AND ITS USE AS A CHEMOPROTECTIVE AND ANTI-MALARIAL AGENT | 06-11-2009 |
20090312437 | Anthraquinones and Analogs from Rhuem palmatum for Treatment of Estrogen Receptor Beta-Mediated Conditions - Compositions derived from | 12-17-2009 |
20100048728 | POLYCYCLIC DIANTHRAQUINONES AS INHIBITORS OF INFLAMMATORY CYTOKINES - The present invention relates to the therapeutic use of polycyclic dianthraquinones including hypericin, helianthrones and helianthrone derivatives as inhibitors of the proinflammatory cytokine cascade mediated inflammatory conditions such as inflammatory bowel disease and cachexia. In addition the compositions can be used for prevention of development of inflammation, fibrosis and vasculopathy as a sequelae induced by irradiation treatment, and to the use thereof, as protective modes for the consequences of irradiation treatment in diseases such as cancers. The present invention can also be used to prevent or improve the inflammatory consequences of infections with viruses or bacteria and to prevent or treat neuroinflammatory disorders. | 02-25-2010 |
20100081724 | PROCESS OF OBTAINMENT OF TRANS-RESVERATROL AND/OR EMODIN AND NUTRACEUTICCAL COMPOSITIONS CONTAINING THEM - Processes for the separation and purification of polyphenol trans-resveratrol and/or anthraquinone emodin from | 04-01-2010 |
20100222437 | COMPOSITION CONTAINING NON-PSYCHOTROPIC CANNABINOIDS FOR THE TREATMENT OF INFLAMMATORY DISEASES - The invention relates to a composition comprising cannabidiol and Denbinobin and its use in medicine, for example, for the prevention and treatment of gastrointestinal inflammatory diseases and for the prevention and treatment of gastrointestinal cancers. | 09-02-2010 |
20110077306 | STAT3 INHIBITING COMPOSITIONS AND METHODS - STA-21-related compounds, for example CLT-005, are shown to prevent dimerization of STAT3, thereby inhibiting STAT3 activity. Inhibition of STAT3 activity is shown to reduce intraocular inflammation and neovascularization, symptoms of eye-related diseases such as age-related macular degeneration. Inhibition of STAT3 prevents STAT3 from transcriptionally activating downstream gene targets that are known to be associated with retinal inflammation and neovascularization and such disorders as age-related macular degeneration. | 03-31-2011 |
20110082215 | ANTHROQUINONE CONTAINING DERIVATIVES AS BIOCHEMICAL AGRICULTURAL PRODUCTS - Formulations containing anthraquinone derivatives with increased effectiveness as pesticides are provided. These formulations may comprise (a) a preparation comprising one or more anthraquinone derivatives having activity against plant pests; (b) one or more C2-C7 alcohols, or glycols or lactones; and (c) one or more surfactants selected from the group consisting of a sulfate, ethoxylated fatty acid esters wherein said alcohols and surfactants are present in amounts effective to stability said preparation. Also provided are methods of using these formulations as pesticides. | 04-07-2011 |
20110218249 | USE OF HYPERICUM PERFORATUM EXTRACTS IN THE TREATMENT OF NEUROPATHIC PAIN - Disclosed is the use of | 09-08-2011 |
20120059067 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE - A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10-dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration topically. The composition may be administered topically to a subject's eye. | 03-08-2012 |
20120129949 | Use of Anthracene Derivatives as Anti-Infectives - The present invention relates to the use of the following anthracene derivatives as anti-infectives, preferably against multiply drug resistant pathogens:
| 05-24-2012 |
20150148428 | MICELLE STRUCTURE OF NANO PREPARATION FOR DIAGNOSIS OR TREATMENT OF CANCER DISEASE AND PREPARATION METHOD THEREOF - Disclosed herein are a nanopreparation having a micelle structure for diagnosis or treatment of cancer diseases, and a method of preparing the same, and more particularly, a nanopreparation having a micelle structure available for diagonosis or treatment of cancer diseases and a method for preparing the same, wherein the nanopreparation is prepared by encapsulating a photosensitizer by forming micelle with polymeric lipid DSPE-mPEG. The nanopreparation having the micelle structure according to the present invention has a size of 12 nm or less by encapsulating hypericin, which is a photosensitizer, by forming micelle with polymeric lipid DSPE-mPEG having a molecular weight of 1500 to 2500. Resultingly, the nanopreparation easily overcomes a blood-tumor barrier (BTB) and an interstitial fluid pressure and has light induced cytotoxicity efficiency that is about more than 2.5 times higher than that of the case where hypericin is used alone. | 05-28-2015 |
514681000 | Bicyclo | 40 |
20090062401 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS - The present invention relates to compounds having a decaline scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said decaline-derived compounds can be used for prophylaxsis and/or treatment of diabetes mellitus type I, diabetes mellitus type II, tuberculosis and other infectious diseases, proliferative diseases, cancer, neurodegenerative diseases, obesity, cognitive dysfunctions and metabolic syndromes. | 03-05-2009 |
20090118377 | APOGOSSYPOLONE AND THE USES THEREOF - The invention relates to the compound apogossypolone and salts and prodrugs thereof. Apogossypolone functions as an inhibitor of Bcl-2 family proteins. The invention also relates to the use of apogossypolone for inhibiting hyperproliferative cell growth, for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death. | 05-07-2009 |
20090318566 | GOSSYPOL DERIVATIVES, PRODUCTION METHOD THEREOF AND USES OF SAME - The present invention relates to compounds of general formula (1): | 12-24-2009 |
20100130618 | TREATMENT OF HUMAN DISEASE CONDITIONS AND DISORDERS USING VITAMIN K ANALOGUES AND DERIVATIVES - The present invention is related to the therapeutic uses of vitamin K, its analogues and derivatives in a diverse array of disease conditions. Vitamin K improves blood perfusion and ameliorates hypoxia in prevention and treatment of conditions such as chronic venous insufficiency manifestations, post thrombotic syndrome, skin conditions related to melanization, hyperpigmentation, Paresthesiae, oedema, varicose veins, VTE and cramps. The invention also provides pharmaceutical compositions comprising vitamin K, its analogues, derivatives or vitamin K-like compounds either alone or in combination with one or more therapeutically effective active agents for the diseases/conditions of venous, nerves and lymph, that are encompassed by this invention. | 05-27-2010 |
20120041072 | Antiviral agent - A compound having inhibitory activity on the binding of a substance α to a PTGS suppressor protein, wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein. | 02-16-2012 |
20120149780 | Method of Use of Vitamin K as Energy Enhancer in Diverse Disease States - The invention relates to Vitamin K, its derivatives and combinations to increase the energy levels in diverse disease states and life style disorders, which are characterized by low energy level due to inadequate VO2 | 06-14-2012 |
20120208893 | NUTRITIONAL COMPOSITIONS FOR MODULATING INFLAMMATION INCLUDING EXOGENOUS VITAMIN K2 - Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof. | 08-16-2012 |
20120238637 | Isolated Extract of Walnuts, Method For Its Obtention And Its Use - The invention refers to an isolated extract of walnuts of high efficiency and stability over time useful for the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases, which is characterized in that it is obtained from a process comprising: i) collecting unripe walnut fruits as raw material; ii) preparing the raw material for the extraction, iii) freezing the raw material prepared in the previous step; iv) drying; v) extracting in a time lower than 10 minutes; vi) filtration; and vii) final packaging. The invention also refers to its use for manufacturing a medicament for the treatment of bacterial, fungal and viral diseases and to a composition comprising it. | 09-20-2012 |
20120309845 | DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING ACUTE MYELOID LEUKEMIA - The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating acute myeloid leukemia in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone. | 12-06-2012 |
20120322889 | PLANT PROTECTION AGENT - The invention relates to the use of a compound according to formula (A) or formula (B), where R1, R4 and R5 are H, a glycoside, or an ester independently of each other, as a plant protection agent, wherein the plant protection agent comprises the compound, which is dissolved in a solvent at a concentration of 0.1 μM to 2 mM. | 12-20-2012 |
20130267606 | USE OF VITAMIN K FOR WEIGHT MAINTENANCE AND WEIGHT CONTROL - Vitamin K is effective in counteracting (1) increase of body weight and body mass index (BMI), (2) accumulation of body fat mass and (3) accelerates weight loss during calory restriction or other life style interventions aiming weight reduction. A pharmaceutical composition or nutritional formulation comprising vitamin K is provided which can be used to combat overweight or obesity, either as a single, dedicated product or in combination with other slimming products or life style change | 10-10-2013 |
20130281544 | HEPATOPROTECTANT ACTIVITY OF GARCINOL - The present invention discloses the hepatoprotective potential of garcinol. | 10-24-2013 |
20140031432 | TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K - Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with vitamin K are disclosed. | 01-30-2014 |
20140194529 | USAGE OF NATURAL COMPOUND FOR TREATING INFLAMMATION AND CANCER - This invention relates to the use of a compound from natural sources for therapeutic uses. More particularly, it relates to a compound, Garcimultiflorone E, naturally occurring in the plant of | 07-10-2014 |
20140194530 | USAGE OF OBLONGIFOLIN C, A NATURAL COMPOUND FROM GARCINIA YUNNANENSIS HU, ON TREATING CANCER AS METASTASIS INHIBITOR AND AUTOPHAGIC FLUX INHIBITOR - Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising | 07-10-2014 |
20150011646 | USAGE OF GUTTIFERONE K, A NATURAL COMPOUND FROM GARCINIA YUNNANENSIS HU ON TREATING HIGH METASTATIC ESOPHAGEAL CANCER - This invention is related to compounds isolated from various | 01-08-2015 |
20150025155 | ANTI-PROSTATE CANCER COMPOUND AND METHOD OF USE THEREOF - Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound. More particularly, it relates to an anti-prostate cancer compound that can be isolated from | 01-22-2015 |
20150051293 | PTEROSIN DERIVATIVE-CONTAINING THERAPEUTIC PREPARATION FOR DISEASE ASSOCIATED WITH CARTILAGE LOSS, CARTILAGE DEGENERATION AND/OR CARTILAGE THINNING - An object of the present invention is to provide a therapeutic preparation and method for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning. The present invention provides a therapeutic preparation comprising a pterosin derivative or a pharmaceutically acceptable salt thereof for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning; and a therapeutic method for the diseases. | 02-19-2015 |
20150133564 | NOVEL COMPOUND, PREPARING METHOD THEREOF, AND USE THEREOF AS INHIBITORS OF HISTONE DEMETHYLASE - Provided are a novel compound, preparing method thereof, and use thereof as inhibitor of histone demethylase. The compound represented by Chemical Formula 1 has activity which inhibits histone demethylase and thus is capable of specifically and effectively inhibit activity of histone demethylase. | 05-14-2015 |
20150141521 | SMALL-MOLECULE INHIBITORS OF DENGUE VIRUS PROTEASES - The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus. | 05-21-2015 |
20160095824 | USE OF VITAMIN K FOR WEIGHT MAINTENANCE AND WEIGHT CONTROL - Vitamin K is effective in counteracting (1) increase of body weight and body mass index (BMI), (2) accumulation of body fat mass and (3) accelerates weight loss during calory restriction or other life style interventions aiming weight reduction. A pharmaceutical composition or nutritional formulation comprising vitamin K is provided which can be used to combat overweight or obesity, either as a single, dedicated product or in combination with other slimming products or life style changes. | 04-07-2016 |
514682000 | Naphthyl ring system | 19 |
20090030086 | ANTIMICROBIAL AGENTS - A benzoquinone or hydroquinone for use in the topical treatment of a condition which is caused, exacerbated or transmitted by bacterial, in particular staphylococcal or propionibacterial, activity. The condition may be a skin or skin structure condition such as acne. The invention also provides the use of a benzo- or hydroquinone in the manufacture of a medicament for the treatment of such a condition. | 01-29-2009 |
20090105350 | Process for the preparation of atovaquone - The present invention provides a process for the preparation of atovaquone exhibiting characteristic peaks (expressed in degrees 2θ±0.2°θ) at approximately one or more of the positions: about 7.0, 9.7, 14.2, 14.8, 17.0, 19.2, 20.4, 22.1, 22.7, 26.9 and 28.7, which comprises: (a) providing a solution comprising atovaquone in an aprotic polar solvent; (b) adding a suitable antisolvent to precipitate atovaquone; and (c) isolating the precipitate. | 04-23-2009 |
20090209652 | Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy - The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. | 08-20-2009 |
20090209653 | AGENT FOR INCREASING TESTOSTERONE LEVEL - Provided is a substance which is a safer and more commonly-consumed food ingredient that increase the testosterone level. The testosterone enhancer of the invention comprises vitamin K as an active ingredient. The vitamin is preferably menaquinone-4 and/or menaquinone-7. This enhancer is useful as pharmaceutical agents, supplements, health foods or functional foods for the prevention, amelioration and/or treatment of a condition or disease induced by the decreased testosterone level. | 08-20-2009 |
20090239952 | VITAMIN K FOR PREVENTION AND TREATMENT OF SKIN RASH SECONDARY TO ANTI-EGFR THERAPY - The invention provides methods and compositions tor treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (BGKR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. | 09-24-2009 |
20100029784 | NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI-INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES - The present invention relates to methods and compositions comprising naphthoquinones such as 2,3-dimethylnaphthalene-1,4-dione, for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible and/or tactile discontinuities of the skin resulting from skin pigmentation or skin aging are also disclosed. | 02-04-2010 |
20100099776 | OILY SUSPENSION OF ATOVAQUONE - The present invention relates to an oily suspension of atovaquone comprising atovaquone particles and a combination of surfactants having HLB more than 10. | 04-22-2010 |
20100152302 | NOVEL CRYSTALLINE FORMS OF ATOVAQUONE - The present invention relates to two novel and stable crystalline forms of atovaquone, to processes for their preparation and to pharmaceutical compositions comprising them. The present invention also provides crystalline particles of atovaquone having a specific surface area of from about 0.7 m | 06-17-2010 |
20100324148 | VITAMIN K FOR PREVENTION AND TREATMENT OF SKIN RASH SECONDARY TO ANTI-EGFR THERAPY - The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. | 12-23-2010 |
20110046233 | GOSSYPOL DERIVATIVES, PRODUCTION METHOD THEREOF AND USES OF SAME - The present invention relates to compounds of general formula (1): | 02-24-2011 |
20120309846 | DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING MYELODYSPLASTIC SYNDROME - The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating myelodysplastic syndrome in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone. | 12-06-2012 |
20120309847 | DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING PROMYELOCYTIC LEUKEMIA - The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating promyelocytic leukemia in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone. | 12-06-2012 |
20130123367 | VINYLOGOUS CHALCONE DERIVATIVES AND THEIR MEDICAL USE - The present invention relates to vinylogous chalcone derivatives, in particular the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these compounds, and their medical use, including their use in the treatment or prevention of cancer, in particular malignant hematological diseases/disorders. | 05-16-2013 |
20130172423 | VITAMIN CONTAINING PRODUCT - A food product comprising menaquinone at a level of 50 to 5,000 μg per 100 g of product. | 07-04-2013 |
20130225690 | VITAMIN K FOR PREVENTION AND TREATMENT OF SKIN RASH SECONDARY TO ANTI-EGFR THERAPY - The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. | 08-29-2013 |
20130237610 | DYNAMIC BALANCING OF AUTONOMIC NERVOUS SYSTEM THROUGH VITAMIN MK-7 - Sympathovagal balance is essential in maintaining internal homeostasis. Imbalance in this can lead to many disease conditions such as cardiovascular diseases, type 2 diabetes mellitus, high blood pressure, gastroesophageal reflux disease (GERD), IBS, depression, COPD, etc. Sudden cardiac death and Myocardial infarction are result of autonomic dysfunction. Many drugs have been proposed for these conditions but lack in correcting the condition and can themselves produce side effects, such as prolongation of QT interval. Inventors of current invention observed serendipitously that vitamin MK-7 can restore the sympathovagal balance and also have cardio protective effect by shortening of QT interval and prolongation of RR interval. Further to this, it was also observed that vitamin MK-7 improves cardiac output, left ventricular work, HDL cholesterol and reduces blood sugar. | 09-12-2013 |
20130345312 | TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES - Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with compounds of Formula (I) are disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods are also disclosed. | 12-26-2013 |
20140336268 | FORMULATIONS OF VITAMIN K ANALOGS FOR TOPICAL USE - The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of dermatological conditions associated with inflammation, particularly, dermatological conditions resulting from anti-EGFR therapies. | 11-13-2014 |
20140343165 | PLANT PROTECTION AGENT - A method for combating bacterial infections in plants including the step of applying a plant protection agent onto the blossoms and/or leaves of the plants. The plant protection agent includes a compound according to formula (A) or formula (B), where R1, R4 and R5 are H, a glycoside, or an ester independently of each other, and the compound is dissolved in a solvent at a concentration of 0.1 μM to 2 mM. | 11-20-2014 |